Aehr Test Systems stock (NASDAQ: AEHR) surges as $100m backlog resets outlook

Aehr Test Systems (NASDAQ: AEHR), a supplier of semiconductor test and burn-in equipment, traded approximately 22% higher at around $88.50 on July 15, 2026, after reporting record quarterly bookings and a sharply stronger fiscal 2027 outlook. The shares rose as high as $110.20 earlier in the session, representing an intraday gain of approximately 53%, before surrendering part of the advance. Effective backlog reached $100.6 million, while management forecast fiscal 2027 revenue of $130 million to $150 million. The central tension is whether Aehr can convert its AI-related orders into durable profitability quickly enough to justify a market capitalisation approaching $2.8 billion.

Why did Aehr Test Systems stock surge after its fiscal 2026 fourth-quarter results?

Aehr Test Systems reported fourth-quarter revenue of $18.8 million, up approximately 34% from $14.1 million in the corresponding fiscal 2025 period. The result was broadly aligned with market revenue expectations, but adjusted earnings of $0.11 per diluted share comfortably exceeded expectations for a small loss.

GAAP net income reached $1.4 million, or $0.04 per diluted share, compared with a $2.9 million loss one year earlier. Non-GAAP net income improved to $3.6 million from a $200,000 loss. The quarterly improvement provided evidence that higher equipment volumes can produce operating leverage, although the GAAP profit included a tax benefit and the company still recorded a quarterly operating loss of approximately $1.2 million.

The larger catalyst was Aehr’s forward outlook. Management expects fiscal 2027 revenue of $130 million to $150 million, representing growth of approximately 160% to 200% from fiscal 2026. The company also expects non-GAAP net income to equal 18% to 22% of revenue.

Trading volume exceeded nine million shares during the session, compared with average daily volume of approximately 2.3 million. Aehr rose despite weakness across several larger semiconductor stocks, strengthening the argument that the rally was driven by company-specific results rather than a broad industry move.

How does Aehr Test Systems’ $100.6 million effective backlog change the growth outlook?

Quarterly bookings reached a record $60.7 million, while backlog stood at $80.6 million at the end of May. Including orders received after the fiscal year-end, effective backlog increased to $100.6 million.

That effective backlog represents approximately 72% of the midpoint of Aehr’s $130 million to $150 million fiscal 2027 revenue guidance. It therefore provides significantly more visibility than the company possessed entering fiscal 2026, when demand timing and customer purchasing decisions produced considerable quarterly volatility.

Backlog is particularly valuable for a smaller semiconductor equipment supplier because individual system orders can materially affect reported revenue. Large equipment shipments may depend on customer facility readiness, production schedules, acceptance testing and installation milestones. Revenue can consequently move between quarters even when underlying demand remains intact.

The effective backlog also provides a test of management’s guidance credibility. Aehr must convert approximately $100.6 million of orders while securing enough additional business to cover the remaining $29.4 million to $49.4 million required to reach its revenue forecast. Recent order activity suggests that target is achievable, but the timing and acceptance of systems will remain important.

Which AI, silicon photonics and power semiconductor markets could drive Aehr’s growth?

Artificial intelligence processors are becoming Aehr’s most important growth opportunity. A lead production customer is expanding capacity and shifting the burn-in of AI accelerators from system-level testing to wafer-level testing. That transition could increase demand for Aehr’s FOX systems and proprietary WaferPak contactors.

Wafer-level burn-in subjects semiconductor devices to elevated electrical and thermal conditions before individual chips are separated from the wafer. Identifying defective chips earlier can reduce the cost of packaging and later-stage testing, which becomes increasingly important as AI accelerators grow more powerful and expensive.

Aehr has also completed benchmark testing with another major supplier of AI accelerators, central processing units and network processors. That potential customer has expressed interest in moving toward pilot-production validation for an existing high-volume device and has requested an evaluation of a second device. A production conversion would broaden Aehr’s customer base, but the evaluation has not yet become a confirmed high-volume programme.

Package-level testing represents another opportunity. Aehr’s Sonoma systems support the burn-in of high-power AI processors after packaging. A hyperscale data-centre customer is expanding its use of Sonoma equipment and is considering additional systems for a second device with approximately twice the power requirements of the current processor.

Silicon photonics could become a separate growth engine as data centres use optical connections to move information more quickly and efficiently. Aehr’s customers are using FOX-XP systems to test photonic devices intended for AI optical input-output and hyperscale data-centre interconnects.

Power semiconductors provide a third source of potential growth. Aehr received approximately $8 million of silicon carbide WaferPak orders during the latest month, including business connected with electric-vehicle programmes. Management also expects improving demand for silicon carbide and gallium nitride devices used in vehicles and data-centre power infrastructure.

Can Aehr Test Systems convert its fiscal 2027 revenue guidance into durable profits?

Fiscal 2026 results show why the guidance represents such a substantial change. Full-year revenue declined approximately 15% to $50 million from $59 million. The GAAP net loss widened to $7.1 million from $3.9 million, while non-GAAP net income declined to $900,000 from $4.6 million.

Cash used in operating activities was $3.3 million. Aehr therefore ended fiscal 2026 with improving quarterly momentum but had not yet demonstrated consistent full-year profitability or positive operating cash generation.

Management’s fiscal 2027 forecast implies non-GAAP net income of approximately $23.4 million at the lowest end of the guidance combinations and as much as $33 million at the upper end. At the midpoint of the ranges, revenue of $140 million and a 20% non-GAAP net income margin would produce approximately $28 million of adjusted profit.

Delivering that margin will require substantial operating leverage. Aehr must manufacture, install and support a much larger volume of equipment while managing component supply, hiring requirements and customer acceptance schedules. Gross profit improved to $8 million in the fourth quarter, producing a gross margin of approximately 42.6%, but research, development and administrative expenses still exceeded quarterly gross profit.

Aehr’s cash position provides financial capacity for the expansion. Cash, cash equivalents and restricted cash reached $116.5 million at the end of May. However, approximately $97.4 million of net cash was raised through public equity offerings, meaning the stronger balance sheet came primarily from investors rather than operating cash flow.

Does Aehr Test Systems’ valuation still offer upside after the latest stock-price surge?

At approximately $88.50 per share, Aehr Test Systems had a market capitalisation of around $2.8 billion. The company does not have a meaningful positive trailing price-to-earnings ratio because it recorded a GAAP loss for fiscal 2026.

Using the midpoint of fiscal 2027 revenue guidance, the stock traded at approximately 20 times projected annual sales. If Aehr achieves around $28 million in midpoint non-GAAP net income, the current market value would represent roughly 100 times that projected adjusted profit.

Those multiples reflect an expectation that fiscal 2027 will be the beginning of a multiyear growth cycle rather than a single strong year. Investors are assigning value to Aehr’s position in AI processor testing, silicon photonics, advanced packaging and power semiconductors, as well as the possibility of additional customer conversions.

The market-performance layer reinforces the level of optimism. Based on the latest available intraday quotation, Aehr shares were approximately 33% higher over five trading days but remained around 20% lower over one month following a steep retreat from their June high.

The stock has gained more than 340% since the beginning of 2026 and over 500% during the past year. Its 52-week range extends from $14.01 to $126.62. Even after the latest rally, the shares remained approximately 30% below the 52-week high but more than six times above the low.

The valuation can be supported if Aehr converts its backlog, expands margins and secures production orders from customers currently conducting evaluations. If fiscal 2027 growth proves heavily concentrated in a few orders or programmes, however, investors may become less willing to apply a premium multiple.

What are the principal risks facing Aehr Test Systems investors after the rally?

The first risk is execution against an unusually large forecast. Fiscal 2027 revenue guidance is between 2.6 and three times fiscal 2026 revenue. Manufacturing capacity, supply-chain availability, customer installations and revenue-recognition timing must all scale rapidly for Aehr to achieve that outlook.

The second risk is customer and programme concentration. Aehr’s backlog appears to include substantial orders from a limited number of AI, hyperscale data-centre and silicon photonics customers. A production delay, design change or capital-spending reduction at one large customer could materially affect quarterly revenue.

The third risk is valuation and shareholder dilution. Aehr’s market capitalisation is high relative to both current revenue and guided adjusted profit. The company also strengthened its cash position through equity issuance, increasing the number of shares among which future earnings must be divided.

These risks should be balanced against the quality of the latest catalyst. Record bookings, $100.6 million of effective backlog, multiple semiconductor end markets and a substantial cash balance give Aehr considerably more visibility than it had one year ago. The issue is no longer whether the company has growth opportunities, but whether it can execute them at the speed now embedded in its share price.

The next formal financial checkpoint is expected to be Aehr’s fiscal 2027 first-quarter report in early October 2026. Before then, investors will be watching for additional orders, pilot-production conversions and evidence that the current backlog is moving into recognised revenue.

What are the key takeaways for Aehr Test Systems investors after the earnings surge?

• Aehr shares traded approximately 22% higher after rising as much as 53% earlier in the July 15 session.
• Fourth-quarter revenue increased approximately 34% to $18.8 million, while non-GAAP earnings reached $0.11 per diluted share.
• Record quarterly bookings of $60.7 million lifted effective backlog to $100.6 million.
• Fiscal 2027 revenue guidance of $130 million to $150 million implies growth of approximately 160% to 200%.
• AI processors, silicon photonics, hyperscale data centres and power semiconductors provide several potential growth channels.
• Aehr’s $116.5 million cash position supports expansion, but much of that liquidity came from equity issuance rather than operations.
• A valuation near 20 times projected fiscal 2027 revenue leaves the stock highly sensitive to order timing, customer concentration and execution.